What Pharmacopoeia Grades Actually Mean
A USP or Ph. Eur. grade designation means that a material has been tested and certified to meet the purity, identity, and quality standards defined in the relevant pharmacopoeia monograph. For white mineral oils, petroleum jellies, paraffin waxes, and microcrystalline waxes — all widely used pharmaceutical excipients — these standards define limits on aromatic hydrocarbons, sulfur content, colour, viscosity, and other critical quality attributes.
The distinction is straightforward but consequential: a pharmacopoeia-grade material has been tested to a defined, internationally recognised standard and comes with documentation — a Certificate of Analysis (CoA) — that confirms batch-specific compliance. A technical-grade material has not been tested to this standard, and using it in a pharmaceutical formulation is a regulatory non-starter in any regulated market.
USP vs Ph. Eur. — Are They the Same?
Not always — and assuming they are is one of the most common procurement errors in pharmaceutical raw material sourcing.
While USP and Ph. Eur. monographs for many excipients have been harmonised through the Pharmacopoeial Discussion Group (PDG) — meaning they share the same test methods and acceptance criteria — there are materials where the two pharmacopoeias diverge in meaningful ways. White mineral oil is a clear example: the USP and Ph. Eur. classify viscosity grades differently, use slightly different purity test parameters, and have different labelling requirements. A material that meets USP specifications does not automatically meet Ph. Eur. requirements, and vice versa.
For pharmaceutical manufacturers supplying both US and EU markets — increasingly the norm for regional producers with export ambitions — dual compliance verification is essential. This means requesting a CoA that explicitly confirms compliance with both pharmacopoeias, or sourcing from a supplier who can provide separate compliance declarations for each market.
The BP (British Pharmacopoeia) is aligned with Ph. Eur. for most excipient monographs, making Ph. Eur.-compliant materials generally acceptable for UK and Commonwealth markets as well. However, always confirm with your regulatory team, particularly for post-Brexit UK submissions.
The Key Pharmaceutical-Grade Materials — What to Know
White Mineral Oils (Liquid Paraffin)
Available in light and heavy grades, selected by kinematic viscosity. USP and Ph. Eur. both have monographs for mineral oil (liquid paraffin) — but grade definitions differ. Used as laxatives (oral liquid paraffin), topical excipients, ointment bases, and lubricants in tablet manufacturing. Aromatic hydrocarbon content is the critical purity parameter — both pharmacopoeias apply strict limits via UV absorbance testing.
Petroleum Jelly (White Soft Paraffin / Petrolatum)
USP Petrolatum and Ph. Eur. White Soft Paraffin are closely aligned but not identical. Both require a white or pale yellow semi-solid with defined melting range, low polycyclic aromatic hydrocarbon content, and an absence of rancidity. Used as an ointment base, topical drug carrier, and protective skin formulation. Snow-white grades are standard for pharmaceutical applications; yellow grades are acceptable for some technical uses but not for patient-contact formulations.
Paraffin Wax (Hard Paraffin)
Ph. Eur. Hard Paraffin and USP Paraffin are both defined by melting point range and purity. Used as a tablet coating component, sustained-release matrix material, and suppository base. Melting point selection is critical — too low and the product loses structural integrity at body temperature; too high and bioavailability is compromised.
Microcrystalline Wax
USP Microcrystalline Wax is used in topical formulations, ointments, and as a pharmaceutical coating material. Its superior oil-binding capacity versus paraffin wax makes it preferable in formulations where phase separation is a stability risk. Ensure USP grade with a current CoA — not all microcrystalline waxes offered commercially meet USP purity specifications.
PVC Compounds in Medical Devices — The DEHP Question
For medical device manufacturers using PVC compounds in tubing, IV bags, blood bags, and fluid transfer systems, the regulatory environment around plasticizers has changed significantly — and procurement teams need to be ahead of it.
DEHP (di(2-ethylhexyl) phthalate) is the traditional plasticizer in flexible medical PVC. It delivers excellent flexibility, processability, and biocompatibility — but its classification as a Substance of Very High Concern (SVHC) under EU REACH, combined with growing restrictions under the EU Medical Device Regulation (MDR), has driven a rapid shift to alternative plasticizers: DINCH (diisononyl cyclohexane-1,2-dicarboxylate), TOTM (trioctyl trimellitate), and DEHT (diethylhexyl terephthalate).
The key issue for procurement is that Ph. Eur. compliance and USP Class VI biocompatibility testing are necessary but not sufficient for DEHP-free applications. You additionally need: confirmation of the specific plasticizer used, the results of migration testing under relevant contact conditions, and — for paediatric and long-term contact devices — an explicit assessment under Annex II of the EU MDR or equivalent. Procurement teams who are only checking pharmacopoeia compliance and missing the plasticizer question are carrying a regulatory risk they may not be aware of.
What to Ask Your Supplier — The Minimum Documentation Package
When qualifying a pharmaceutical-grade raw material supplier, the documentation package should include at minimum:
- Certificate of Analysis (CoA) — batch-specific, signed, with test results against pharmacopoeia specifications
- Pharmacopoeia compliance declaration — explicitly stating USP, Ph. Eur., or both
- Safety Data Sheet (SDS) — current, GHS-compliant
- Technical Data Sheet (TDS) — physical and chemical properties
- Excipient Information Package (EIP) or equivalent — for formal regulatory submissions
- Change notification protocol — written commitment to notify you of any manufacturing site, process, or source changes before they occur
The last point is frequently overlooked and frequently the source of compliance surprises. A supplier who changes raw material source or refining process without notification forces you into an unplanned requalification — with all the time and cost that entails.
The Regional Supply Advantage
For pharmaceutical manufacturers in the Middle East and Africa, sourcing pharmacopoeia-grade excipients from a regional partner with ready stock offers a material advantage over direct import from European or North American manufacturers: lead time.
In pharmaceutical manufacturing, raw material lead time directly affects production scheduling flexibility and safety stock requirements. A supplier shipping from Europe on long lead times forces you to carry significantly more safety stock — tying up working capital and warehouse space. A regional supplier with stock already in the region allows leaner inventory management without supply risk.
The caveat is that regional availability of pharmacopoeia-grade materials cannot come at the expense of documentation quality. The right regional partner provides the same documentation standard as the originating manufacturer — not a summary CoA or a forwarded document from a previous shipment.